nach oben

Die Innere Medizin

Erschienen in:

01.04.2015 | Schwerpunkt

Haarzellleukämie

verfasst von: S. Dietrich, M. Andrulis, Prof. Dr. T. Zenz

Erschienen in: Die Innere Medizin | Ausgabe 4/2015

Einloggen, um Zugang zu erhalten

Zusammenfassung

Im Jahr 1958 wurde die Haarzellleukämie erstmals als eigenständige Entität beschrieben. Es ist eine sehr seltene maligne Erkrankung der B-Lymphozyten, die durch einen indolenten Verlauf gekennzeichnet ist. Therapieregime auf Basis von Purinanaloga haben die Prognose entscheidend verbessert. Dieser Übersichtsbeitrag fasst das pathophysiologische Verständnis der Haarzellleukämie und die Entwicklung der Therapie zusammen.

Andrulis M, Penzel R, Weichert W et al (2012) Application of a BRAF V600E mutation-specific antibody for the diagnosis of hairy cell leukemia. Am J Surg Pathol 36:1796–1800CrossRefPubMed

Arcaini L, Zibellini S, Boveri E et al (2012) The BRAF V600E mutation in hairy cell leukemia and other mature B-cell neoplasms. Blood 119:188–191CrossRefPubMed

Blombery PA, Wong SQ, Hewitt CA et al (2012) Detection of BRAF mutations in patients with hairy cell leukemia and related lymphoproliferative disorders. Haematologica 97:780–783CrossRefPubMedCentralPubMed

Bouroncle BA, Wiseman BK, Doan CA (1958) Leukemic reticuloendotheliosis. Blood 13:609–630PubMed

Burotto M, Stetler-Stevenson M, Arons E et al (2013) Bendamustine and rituximab in relapsed and refractory hairy cell leukemia. Clin Cancer Res 19:6313–6321CrossRefPubMed

Callahan MK, Rampal R, Harding JJ et al (2012) Progression of RAS-mutant leukemia during RAF inhibitor treatment. N Engl J Med 367:2316–2321

Cassileth PA, Cheuvart B, Spiers AS et al (1991) Pentostatin induces durable remissions in hairy cell leukemia. J Clin Oncol 9:243–246

Chung SS, Kim E, Park JH et al (2014) Hematopoietic stem cell origin of BRAFV600E mutations in hairy cell leukemia. Sci Transl Med 6:238ra271

Dearden CE, Else M, Catovsky D (2011) Long-term results for pentostatin and cladribine treatment of hairy cell leukemia. Leuk Lymphoma 52(Suppl 2):21–24CrossRefPubMed

10.

Del Giudice I, Matutes E, Morilla R et al (2004) The diagnostic value of CD123 in B-cell disorders with hairy or villous lymphocytes. Haematologica 89:303–308

11.

Dietrich S, Glimm H, Andrulis M et al (2012) BRAF inhibition in refractory hairy-cell leukemia. N Engl J Med 366:2038–2040

12.

Dietrich S, Hullein J, Hundemer M et al (2013) Continued response off treatment after BRAF inhibition in refractory hairy cell leukemia. J Clin Oncol 31:e300–e303

13.

Dietrich S, Pircher A, Andrulis A et al (2014) BRAF inhibition in hairy cell leukemia: multicentre experience of 21 patients treated with vemurafenib. ASH, San Francisco

14.

Downward J (2011) Targeting RAF: trials and tribulations. Nat Med 17:286–288CrossRefPubMed

15.

Else M, Dearden CE, Matutes E et al (2011) Rituximab with pentostatin or cladribine: an effective combination treatment for hairy cell leukemia after disease recurrence. Leuk Lymphoma 52(Suppl 2):75–78CrossRefPubMed

16.

Else M, Dearden CE, Matutes E et al (2009) Long-term follow-up of 233 patients with hairy cell leukaemia, treated initially with pentostatin or cladribine, at a median of 16 years from diagnosis. Br J Haematol 145:733–740CrossRefPubMed

17.

Else M, Osuji N, Forconi F et al (2007) The role of rituximab in combination with pentostatin or cladribine for the treatment of recurrent/refractory hairy cell leukemia. Cancer 110:2240–2247CrossRefPubMed

18.

Flaherty KT, Puzanov I, Kim KB et al (2010) Inhibition of mutated, activated BRAF in metastatic melanoma. N Engl J Med 363:809–819

19.

Flinn IW, Kopecky KJ, Foucar MK et al (2000) Long-term follow-up of remission duration, mortality, and second malignancies in hairy cell leukemia patients treated with pentostatin. Blood 96:2981–2986PubMed

20.

Follows GA, Sims H, Bloxham DM et al (2013) Rapid response of biallelic BRAF V600E mutated hairy cell leukaemia to low dose vemurafenib. Br J Haematol 161:150–153CrossRefPubMed

21.

Gerrie AS, Zypchen LN, Connors JM (2012) Fludarabine and rituximab for relapsed or refractory hairy cell leukemia. Blood 119:1988–1991CrossRefPubMed

22.

Grever M, Kopecky K, Foucar MK et al (1995) Randomized comparison of pentostatin versus interferon alfa-2a in previously untreated patients with hairy cell leukemia: an intergroup study. J Clin Oncol 13:974–982

23.

Grever MR (2010) How I treat hairy cell leukemia. Blood 115:21–28CrossRefPubMedCentralPubMed

24.

Habermann TM, Rai K (2011) Historical treatments of in hairy cell leukemia, splenectomy and interferon: past and current uses. Leuk Lymphoma 52(Suppl 2):18–20CrossRefPubMed

25.

Hallek M, Fischer K, Fingerle-Rowson G et al (2010) Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial. Lancet 376:1164–1174CrossRefPubMed

26.

Ho AD, Ganeshaguru K, Knauf W et al (1989) Enzyme activities of leukemic cells and biochemical changes induced by deoxycoformycin in vitro – lack of correlation with clinical response. Leuk Res 13:269–278CrossRefPubMed

27.

Ho AD, Thaler J, Mandelli F et al (1989) Response to pentostatin in hairy-cell leukemia refractory to interferon-alpha. The European Organization for Research and Treatment of Cancer Leukemia Cooperative Group. J Clin Oncol 7:1533–1538

28.

Jethwa A, Hullein J, Stolz T et al (2013) Targeted resequencing for analysis of clonal composition of recurrent gene mutations in chronic lymphocytic leukaemia. Br J Haematol 163:496–500CrossRefPubMed

29.

Jones G, Parry-Jones N, Wilkins B et al (2012) Revised guidelines for the diagnosis and management of hairy cell leukaemia and hairy cell leukaemia variant*. Br J Haematol 156:186–195CrossRefPubMed

30.

Kreitman RJ (2012) Immunoconjugates and new molecular targets in hairy cell leukemia. Hematology Am Soc Hematol Educ Program 2012:660–666PubMed

31.

Kreitman RJ, Arons E, Stetler-Stevenson M et al (2011) Recombinant immunotoxins and other therapies for relapsed/refractory hairy cell leukemia. Leuk Lymphoma 52(Suppl 2):82–86CrossRefPubMed

32.

Kreitman RJ, Stetler-Stevenson M, Margulies I et al (2009) Phase II trial of recombinant immunotoxin RFB4(dsFv)-PE38 (BL22) in patients with hairy cell leukemia. J Clin Oncol 27:2983–2990

33.

Kreitman RJ, Tallman MS, Robak T et al (2012) Phase I trial of anti-CD22 recombinant immunotoxin moxetumomab pasudotox (CAT-8015 or HA22) in patients with hairy cell leukemia. J Clin Oncol 30:1822–1828

34.

Kreitman RJ, Wilson WH, White JD et al (2000) Phase I trial of recombinant immunotoxin anti-Tac(Fv)-PE38 (LMB-2) in patients with hematologic malignancies. J Clin Oncol 18:1622–1636

35.

Lauria F, Forconi F (2009) Combination therapies to improve the long-term outcome in hairy cell leukemia. Leuk Lymphoma 50(Suppl 1):18–22CrossRefPubMed

36.

Malfuson JV, Fagot T, Konopacki J et al (2010) Which role for rituximab in hairy cell leukemia? Reflections on six cases. Acta Haematol 123:110–116CrossRefPubMed

37.

Maurer H, Haas P, Wengenmayer T et al (2014) Successful vemurafenib salvage treatment in a patient with primary refractory hairy cell leukemia and pulmonary aspergillosis. Ann Hematol 93:1439–1440CrossRefPubMed

38.

Munoz J, Schlette E, Kurzrock R (2013) Rapid response to vemurafenib in a heavily pretreated patient with hairy cell leukemia and a BRAF mutation. J Clin Oncol 31:e351–e352

39.

Nieva J, Bethel K, Saven A (2003) Phase 2 study of rituximab in the treatment of cladribine-failed patients with hairy cell leukemia. Blood 102:810–813CrossRefPubMed

40.

Park J, Chung S, Chung Y et al (2013) Phase II trial of the BRAF inhibitor, vemurafenib, in patients with BRAF mutant relapsed or refractory hairy cell leukemia. ASH, New Orleans

41.

Peyrade F, Re D, Ginet C et al (2013) Low-dose vemurafenib induces complete remission in a case of hairy-cell leukemia with a V600E mutation. Haematologica 98:e20–e22CrossRefPubMedCentralPubMed

42.

Prahallad A, Sun C, Huang S et al (2012) Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR. Nature 483:100–103CrossRefPubMed

43.

Ravandi F, O’Brien S, Jorgensen J et al (2011) Phase 2 study of cladribine followed by rituximab in patients with hairy cell leukemia. Blood 118:3818–3823CrossRefPubMedCentralPubMed

44.

Robak T, Jamroziak K, Gora-Tybor J et al (2007) Cladribine in a weekly versus daily schedule for untreated active hairy cell leukemia: final report from the Polish Adult Leukemia Group (PALG) of a prospective, randomized, multicenter trial. Blood 109:3672–3675CrossRefPubMed

45.

Robert C, Karaszewska B, Schachter J et al (2015) Improved overall survival in melanoma with combined dabrafenib and trametinib. N Engl J Med 372:30–39

46.

Samuel J, Macip S, Dyer MJ (2014) Efficacy of vemurafenib in hairy-cell leukemia. N Engl J Med 370:286–288

47.

Saven A, Burian C, Koziol JA et al (1998) Long-term follow-up of patients with hairy cell leukemia after cladribine treatment. Blood 92:1918–1926PubMed

48.

Su F, Bradley WD, Wang Q et al (2012) Resistance to selective BRAF inhibition can be mediated by modest upstream pathway activation. Cancer Res 72:969–978CrossRefPubMed

49.

Swerdlow SH, Campo E, Harris NL et al (2008) WHO classification of tumours of haematopoietic and lymphoid tissues, fourth edition. IARC Press, Lyon

50.

Tallman MS (2011) Implications of minimal residual disease in hairy cell leukemia after cladribine using immunohistochemistry and immunophenotyping. Leuk Lymphoma 52(Suppl 2):65–68CrossRefPubMed

51.

Thomas DA, O’Brien S, Bueso-Ramos C et al (2003) Rituximab in relapsed or refractory hairy cell leukemia. Blood 102:3906–3911CrossRefPubMed

52.

Tiacci E, Falini B (2014) Efficacy and safety of the BRAF inhibitor vemurafenib in hairy cell leukemia patients refractory to or relapsed after purine analogs: a phase-2 italian clinical trial. EHA, Mailand

53.

Tiacci E, Trifonov V, Schiavoni G et al (2011) BRAF mutations in hairy-cell leukemia. N Engl J Med 364:2305–2315

54.

Waterfall JJ, Arons E, Walker RL et al (2014) High prevalence of MAP2K1 mutations in variant and IGHV4-34-expressing hairy-cell leukemias. Nat Genet 46:8–10CrossRefPubMedCentralPubMed

55.

Xi L, Arons E, Navarro W et al (2012) Both variant and IGHV4-34-expressing hairy cell leukemia lack the BRAF V600E mutation. Blood 119:3330–3332CrossRefPubMedCentralPubMed

56.

Zenhausern R, Schmitz SF, Solenthaler M et al (2009) Randomized trial of daily versus weekly administration of 2-chlorodeoxyadenosine in patients with hairy cell leukemia: a multicenter phase III trial (SAKK 32/98). Leuk Lymphoma 50:1501–1511CrossRefPubMed

57.

Zinzani PL, Pellegrini C, Stefoni V et al (2010) Hairy cell leukemia: evaluation of the long-term outcome in 121 patients. Cancer 116:4788–4792CrossRefPubMed

58.

Zinzani PL, Tani M, Marchi E et al (2004) Long-term follow-up of front-line treatment of hairy cell leukemia with 2-chlorodeoxyadenosine. Haematologica 89:309–313PubMed

Titel: Haarzellleukämie
verfasst von: S. Dietrich
M. Andrulis
Prof. Dr. T. Zenz
Publikationsdatum: 01.04.2015
Verlag: Springer Berlin Heidelberg
Erschienen in: Die Innere Medizin / Ausgabe 4/2015
Print ISSN: 2731-7080
Elektronische ISSN: 2731-7099
DOI: https://doi.org/10.1007/s00108-014-3599-2

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

19.04.2024 | Vorhofflimmern | Nachrichten

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Haarzellleukämie

Zusammenfassung

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Parodontalbehandlung verbessert Prognose bei Katheterablation

Prostatakarzinom: EU initiiert neues Screeningkonzept

Blasenkarzinom – Biomarker statt Zytologie?

Antihypertensiva schützen auch alte Menschen noch vor Demenz

Update Innere Medizin

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Zusammenfassung

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 4/2015

BDI-Kongresse

Molekulare Ursachen der Leukämien

HDL und atherosklerotisch verursachte kardiovaskuläre Erkrankungen

Mitteilungen des BDI

Mitteilungsseiten der DGIM

Chronische lymphatische Leukämie

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Parodontalbehandlung verbessert Prognose bei Katheterablation

Prostatakarzinom: EU initiiert neues Screeningkonzept

Blasenkarzinom – Biomarker statt Zytologie?

Antihypertensiva schützen auch alte Menschen noch vor Demenz

Update Innere Medizin